Clovis CEO's Rough Guide To European Launches
Local knowledge on the regulatory and commercial fronts is an absolute must to succeed in Europe, Patrick Mahaffy tells Scrip a couple of months after the firm's PARP inhibitor Rubraca hit the German market.
You may also be interested in...
The UK major is marking its return to oncology by spending over $5bn to get hold of Tesaro and its PARP inhibitor Zejula. The question now is whether it will be able to catch AstraZeneca's market-leading Lynparza.
Vitrakvi is effective against a wide variety of cancers driven by NTRK fusion. But finding the patients who will benefit will be a challenge, given there are expected to be only around 2,500 to 3,000 new cases in the US and testing for the mutation is uncommon.
Clovis is looking a steal a march on its rival PARP inhibitors and hopes to be the first drug in the class to get approval for prostate cancer following strong data seen in the TRITON trial.